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Objectives: To develop European League Against
Rheumatism (EULAR) recommendations for the manage-
ment of large vessel vasculitis.
Methods: An expert group (10 rheumatologists, 3
nephrologists, 2 immunolgists, 2 internists representing 8
European countries and the USA, a clinical epidemiologist
and a representative from a drug regulatory agency)
identified 10 topics for a systematic literature search
through a modified Delphi technique. In accordance with
standardised EULAR operating procedures, recommenda-
tions were derived for the management of large vessel
vasculitis. In the absence of evidence, recommendations
were formulated on the basis of a consensus opinion.
Results: Seven recommendations were made relating to
the assessment, investigation and treatment of patients
with large vessel vasculitis. The strength of recommen-
dations was restricted by the low level of evidence and
EULAR standardised operating procedures.
Conclusions: On the basis of evidence and expert
consensus, management recommendations for large
vessel vasculitis have been formulated and are com-
mended for use in everyday clinical practice.
The large vessel vasculitides affect the aorta and
its branches and include giant cell arteritis and
Takayasu arteritis, which are anatomically, epide-
miologically and clinically distinct conditions. The
estimated incidence of giant cell arteritis in
Europe, in individuals aged over 50 years of age
varies between 32 and 290/million/year, making it
the commonest primary systemic vasculitis in
adulthood.1–10 There are few studies reporting the
incidence of giant cell arteritis outside of Europe:
102/million/year in Jerusalem11 and 188/million/
year in Minnesota, USA.12 Giant cell arteritis has a
prevalence of 240–1354/million in Northern
Europe in individuals over 50 years of age.5 13 It
has an affinity to affect the branches of the
carotid artery, but subclinical involvement of the
other cranial arteries and the wider arterial tree is
not uncommon.14 15 Takayasu arteritis is less
common than giant cell arteritis. The annual
incidence of Takayasu arteritis is 0.4–2/million/
year and the frequency in an autopsy study from
Japan was 0.033%.1 16 17 These conditions present a
challenge to diagnosis and management. This
paper summarises seven evidence-based recom-
mendations for the management of the large
vessel vasculitides.
METHODS
These recommendations have been developed
according to standardised operating procedures, as
developed by the European League Against
Rheumatism (EULAR) standing committees.18
This guidance is termed ‘‘recommendations’’ as
opposed to ‘‘guidelines’’ or ‘‘points to consider’’ as
the evidence base is strong to provide guidance but
not in itself sufficient to answer the needs of the
individual patient. They will need to be tailored to
individual needs. These recommendations are
intended for use by healthcare professionals who
look after patients with primary systemic vasculi-
tis, for the training of medical students and
specialist trainees, and for pharmaceutical indus-
tries and drug regulatory organisations.
The committee was convened by RL (rheuma-
tologist) and LG (internist) and consisted of nine
rheumatologists (BD, KdG, WG, BH, PM, CaS, DS,
RW, HY), three renal doctors (CoS, DJ, KW), two
immunologists (CK, TH), one internist (MC), one
clinical epidemiologist (HR) and one US Food and
Drug Administration (FDA) representative (JW).
The specialty of each author was self-declared. CM
was appointed as the clinical fellow in charge of
the literature search.
Prior to the literature search, a modified Delphi
among the experts was carried out to identify the
scope of the recommendations. The Delphi process
identified 10 points to focus the literature search.
Following the Delphi exercise, the committee agreed
on the search string to identify the publications in
PubMed: for example, ‘‘Takayasu’s arteritis’’[Mesh]
AND (‘‘Epidemiologic Study Characteristics’’[Mesh]
OR ‘‘Evaluation Studies’’[Mesh] OR ‘‘Study
Characteristics’’ [Publication Type]) NOT ‘‘Case
Reports’’ [Publication Type]. For giant cell arteritis,
the medical subject heading used in PubMed and the
search string was ‘‘Temporal arteritis’’. All papers
identified in Medline were then limited to manu-
scripts indexed for adult patients and those having
abstracts. The search was not limited to a time frame
or by language. The Cochrane library was searched
using the disease specific keywords. A manual search
of abstracts presented at the annual meetings of the
British Society for Rheumatology and the European
League Against Rheumatism for the year 2007 and
the American College of Rheumatology (ACR) for
the year 2006 was performed.
Each paper was reviewed and included if it
contained a management outcome as identified in
the modified Delphi exercise. Duplicate datasets
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were discarded. The identified papers were then categorised and
given a level of evidence according to internationally accepted
criteria (table 1).18 The evidence was assimilated into seven
statements. Each statement was voted on by the members of
the steering committee according to internationally agreed
criteria (table 2)18 and we present the median vote for each
statement. In the absence of evidence some statements are
based on expert opinion and the level of evidence reflects the
same.
RESULTS
The modified Delphi exercise
The items of the modified Delphi search on which there was
agreement, are given in table 3. It was recognised that some of
the items may not have an evidence base to formulate
recommendations.
Literature search
The results of the literature search are as in table 4. Cochrane
reviews added no further studies. The manual search of the
abstract of meetings in 2006 did not reveal any abstracts with
enough details of management outcomes to warrant inclusion.
Statements
1. We recommend a thorough clinical and imaging assessment of the
arterial tree when a diagnosis of Takayasu arteritis is suspected
(level of evidence 3, strength of recommendation C)
In the absence of a gold standard for the diagnosis and
monitoring of patients with Takayasu arteritis, a clinical
suspicion of vasculitis should trigger a thorough clinical
examination of the arterial tree.19–24 Magnetic resonance
angiography or positron emission tomography can assist
diagnosis and document the extent of the arterial involvement,
but these modalities require formal validation.25–28 They are not
widely available and remain operator dependent. In their
absence, conventional angiography should be considered.
Takayasu arteritis should be managed at an expert centre
because of the rarity of the disease, the limited availability of
specialist imaging, specialist vascular surgery and the difficulty
associated with treating this condition.19 20 29 30
2. A temporal artery biopsy should be performed whenever a
diagnosis of giant cell arteritis is suspected, but this should not delay
the treatment; a contralateral biopsy is not routinely indicated (level
of evidence 3, strength of recommendation C)
A biopsy of the affected temporal artery should always be
attempted whenever possible. Histopathological evidence is the
gold standard for the diagnosis of giant cell arteritis. It is not a
sensitive procedure and the presence of skip lesions may render
the test negative.31–36 Routine biopsy of both temporal arteries is
not recommended because this does not add significantly to the
diagnostic yield; although it may be of value in selected
individuals.37–39 An adequate sample length is important when
a biopsy is carried out and we suggest a biopsy length of at least
1 cm to enable the pathologist to look at multiple sections of
the artery over a wide area.40–42 Due to the possibility of a false
negative result, and the risk of irreversible ocular involvement,
treatment with high-dose glucocorticoids should be commenced
on strong clinical suspicion of giant cell arteritis, prior to the
biopsy to be carried out.43–46 Treatment prior to biopsy is
unlikely to affect the result of the test, but the biopsy should
not be delayed beyond 1–2 weeks of commencing glucocorticoid
therapy.47 48
Raised inflammatory markers are highly sensitive for the
diagnosis of giant cell arteritis. A normal erythrocyte sedimen-
tation rate or C-reactive protein should raise suspicion for an
alternative diagnosis.49 50 In a meta-analysis of studies, ultra-
sonography of the temporal artery was 88% sensitive and 97%
specific for diagnosing temporal arteritis.51 It can demonstrate
changes thought to be due to vessel wall oedema. This test
awaits multicentre reproducibility.
3. We recommend early initiation of high-dose glucocorticoid therapy
for induction of remission in large vessel vasculitis (level of evidence
3, strength of recommendation C)
Early intensive therapy with high-dose glucocorticoid induces
remission in patients with large vessel vasculitis.19 52 53 Visual
loss in one eye is prevalent in 18% of patients at diagnosis.54 It is
usually irreversible and pulsed intravenous methylprednisolone
may be of benefit to some patients who present early following
the onset of visual symptoms.45 55–59 The initial dose of
prednisolone is 1 mg/kg/day (maximum 60 mg/day) and the
initial high-dose should be maintained for a month and tapered
gradually.19 21 52 54 60 The taper should not be in the form of
alternate day therapy, as this is more likely to lead to a relapse
of vasculitis.60 At 3 months, the glucocorticoid dose in clinical
trials has been between 10–15 mg/day.53 54 61 62 The duration of
glucocorticoid therapy for patients with giant cell arteritis is
variable and can extend to several years, but some patients may
not be able to tolerate complete discontinuation of glucocorti-
coid therapy due to recurrent disease or secondary adrenal
insufficiency.52 All patients should have bone protection therapy
in the absence of contraindications in accordance with local
guidelines.63
4. We recommend that an immunosuppressive agent should be
considered for use in large vessel vasculitis as adjunctive therapy
(level of evidence 1A for giant cell arteritis, strength of
recommendation B; level of evidence 3 for Takayasu arteritis,
strength of recommendation C)
Giant cell arteritis requires long-term glucocorticoid therapy;
86% of patients suffer glucocorticoid-related adverse events at
Table 1 Determination of level of evidence: the data from studies was
graded according to internationally accepted criteria
Category Evidence
1A From meta-analysis of randomised controlled trials
1B From at least one randomised controlled trial
2A From at least one controlled study without randomisation
2B From at least one type of quasi-experimental study
3 From descriptive studies, such as comparative studies, correlation
studies, or case–control studies
4 From expert committee reports or opinions and/or clinical
experience of respected authorities
Trial methodology and other uncontrolled results from any of the studies (including
randomised controlled trials) were awarded a lower level of evidence.
Table 2 Determination of strength of recommendation
Strength Directly based on:
A Category 1 evidence
B Category 2 evidence or extrapolated recommendations from
category 1 evidence
C Category 3 evidence or extrapolated recommendations from
category 1 or 2 evidence
D Category 4 evidence or extrapolated recommendations from
category 2 or 3 evidence
Recommendation
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10-year follow-up.52 In an effort to reduce the duration of
glucocorticoid therapy, there have been three randomised
controlled trials of methotrexate as adjunctive therapy to
glucocorticoid.54 62 64 A meta-analysis of these three trials
demonstrates a modest role for methotrexate (10–15 mg/week)
in reducing relapse rate and lowering the cumulative dose of
glucocorticoid therapy.65 The combination of infliximab and
glucocorticoid therapy does not reduce the risk of relapse as
compared to glucocorticoid monotherapy, and is not recom-
mended in giant cell arteritis.61
Despite glucocorticoid therapy, Takayasu arteritis can remain
active at a subclinical level.66 Azathioprine (2 mg/kg/day) and
methotrexate (20–25 mg/week) have been used as adjuncts to
glucocorticoid therapy in patients with Takayasu arteritis.21 67 68
The addition of these agents to glucocorticoid may help to
improve disease control and facilitate reduction of the cumu-
lative glucocorticoid dose. Cyclophosphamide has been used in
adults with Takayasu arteritis resistant to glucocorticoids in a
small open label study.69
5. Monitoring of therapy for large vessel vasculitis should be clinical
and supported by measurement of inflammatory markers (level of
evidence 3, strength of recommendation C)
There are no valid biomarkers for assessing response and
diagnosing relapse in large vessel vasculitis. Clinical monitoring
aided by inflammatory markers should inform the decision to
alter therapy. For patients with Takayasu arteritis, periodic
imaging with MRI may assist assessment of disease activity.25 26
Positron emission tomography may also be of value for
monitoring.28 There is limited evidence for the use of carotid
and subclavian ultrasonography for monitoring of Takayasu
arteritis.70–72 All the imaging modalities need formal validation
for monitoring of vasculitis activity. All patients with Takayasu
arteritis will need long-term monitoring.
For patients with giant cell arteritis, a relapse is usually
associated with a rise in erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP). Aortic imaging should be
considered in giant cell arteritis, especially in patients with an
aortic insufficiency murmur,73 because subclinical involvement
is common and may progress to form aneurysm or dissection in
9%–18% of patients.14 73–76 In symptomatic patients, the
presence of normal inflammatory markers should raise suspicion
of an alternative diagnosis. Patients in clinical remission who
have discontinued therapy and experience a relapse should be
treated as per new patients. For those still on glucocorticoids, an
increase of 5–10 mg/day may be sufficient to treat the relapse.54
Increase to a full remission induction dose of glucocorticoid
(1 mg/kg/day) is not usually necessary unless ocular or
neurological symptoms recur.
6. We recommend the use of low-dose aspirin in all patients with
giant cell arteritis (level of evidence 3, strength of recommendation
C)
Patients with giant cell arteritis are at an increased risk of
developing cardiovascular and cerebrovascular events.74 77 The
addition of low-dose aspirin (75–150 mg/day) protects against
such events and should be prescribed to all patients in the
absence of contraindications.78 79 Gastroduodenal mucosal pro-
tection should be considered when commencing aspirin. The
use of hydroxymethylglutaryl coenzyme A reductase inhibitors
(statins) does not seem to be influence the clinical profile or
glucocorticoid requirement of patients with giant cell arter-
itis80 81
7. Reconstructive surgery for Takayasu arteritis should be performed
in the quiescent phase of disease and should be undertaken at expert
centres (level of evidence 3, strength of recommendation C)
Arterial reconstruction and bypass grafting may be necessary in
up to 70% of patients with Takayasu arteritis to reverse some of
the features of the disease, for example renovascular hyperten-
sion.19–21 82 In expert hands, reconstructive surgery has a good
outcome, but revision surgery is often needed.19 29 30 83 84
Table 3 Results of the modified Delphi: 10 topics that the committee agreed to address
No. Topic Coverage
1 Diseases to be addressed WG, MPA, CSS, PAN, cryoglobulinemic vasculitis, GCA, Takayasu arteritis
2 Initial assessment Involvement of expert centres, structured clinical examination, role of ANCA, staging of
disease, biopsy
3 Remission induction Cyclophosphamide, methotrexate, high-dose glucocorticoids
Doses, route of administration, regimen of intravenous use, prophylaxis against
Pneumocystis jiroveci and osteoporosis, tapering of glucocorticoids, bladder protection,
antiemetic therapy, monitoring for drug toxicity, plasmapheresis
4 Remission maintenance Choice of immunomodulator, length of treatment, co-trimoxazole
5 Relapsing disease Choice of immunomodulator, referral to expert centre
6 Refractory disease Choice of immunomodulator, experimental therapies
7 Cryoglobulinemic vasculitis Choice of therapy, antiviral therapy
8 Polyarteritis nodosa Choice of therapy, antiviral therapy
9 Monitoring and follow-up Structured clinical examination, blood test monitoring, urine analysis, vaccination, fertility
and contraception
10 Complications of disease Anaemia, hypertension, thromboprophylaxis, reconstructive surgery, renal protection
ANCA, anti-neutrophilic cytoplasmic antibodies; CSS, Churg–Strauss syndrome; GCA, giant cell arteritis; MPA, microscopic
polyangiitis; PAN, polyarteritis nodosa; WG, Wegener granulomatosis.
Table 4 Results of the literature search on 31/08/2007: number of papers identified in PubMed
Keyword used in search string No. of identified citations Restricted to ‘‘adult’’ and ‘‘abstract’’ Unique citations
Temporal arteritis 508 371 371
Takayasu arteritis 274 207 195
Total no of identified citations 566
Recommendation
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Angioplasty and stent insertion have a higher rate of restenosis
than surgical reconstruction, but may be appropriate for some
patients.19 84–86 Elective procedures should be performed when
disease is in remission.19 30 These patients will need long-term
follow-up.30 87 88
DISCUSSION
Application of these recommendations
Giant cell arteritis and Takayasu arteritis affect different age
groups and have a different disease burden. Yet, many of the
clinical manifestations and pathological findings in these
disorders overlap. Furthermore, the principles of managing
these two conditions are similar.
To produce these recommendations (table 5), we have
performed a systematic review of literature and have applied
internationally accepted grading criteria of clinical trials and
studies.18 The absence of many large clinical trials in these
conditions prevents us from supporting some of the statements
with stronger grades. For example, the use of glucocorticoid
therapy in large vessel vasculitis is universally accepted but the
lack of evidence based on clinical trials meant that the level of
evidence could only be 3 (descriptive studies), leading to a grade
of recommendation no higher than C. Our final recommenda-
tions represent the distillation of evidence and experience of an
international group of doctors with an expertise in the
management in these conditions. The project has also led to
the committee to propose a research agenda for large vessel
vasculitis (box 1). We hope that these recommendations will
assist individual clinicians in the management of these condi-
tions, and provide a tool for auditing their practice.
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